Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Deshotels, Matthew R.; Virani, Salim S.; Ballantyne, Christie M.

doi:10.1007/s11886-021-01545-9

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although current progress in medicine allows for the development of new modern drugs for the treatment for atherosclerosis, an appropriate level of cholesterol is challenging to achieve even when agents such as statins, fibrates, niacin and antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9) are used in clinical practice [58]. Thereby, since there is a trend of increasing prevalence of cardiovascular diseases, it is now clear that new pharmaceutical formulations are necessary to improve the prognosis of patients at risk for CVDs.…”

Section: Nanomaterial-based Drug Targeted Therapy For Atherosclerosismentioning

confidence: 99%

Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis

et al. 2021

View full text Add to dashboard Cite

Cardiovascular diseases (CVDs) represent the most important epidemic of our century, with more than 37 million patients globally. Furthermore, CVDs are associated with high morbidity and mortality, and also increased hospitalization rates and poor quality of life. Out of the plethora of conditions that can lead to CVDs, atherosclerosis and ischemic heart disease are responsible for more than 2/3 of the cases that end in severe heart failure and finally death. Current therapy strategies for CVDs focus mostly on symptomatic benefits and have a moderate impact on the underlying physiopathological mechanisms. Modern therapies try to approach different physiopathological pathways such as reduction of inflammation, macrophage regulation, inhibition of apoptosis, stem-cell differentiation and cellular regeneration. Recent technological advances make possible the development of several nanoparticles used not only for the diagnosis of cardiovascular diseases, but also for targeted drug delivery. Due to their high specificity, nanocarriers can deliver molecules with poor pharmacokinetics and dynamics such as: peptides, proteins, polynucleotides, genes and even stem cells. In this review we focused on the applications of nanoparticles in the diagnosis and treatment of ischemic heart failure and atherosclerosis.

show abstract

Section: Nanomaterial-based Drug Targeted Therapy For Atherosclerosismentioning

confidence: 99%

Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis

et al. 2021

View full text Add to dashboard Cite

show abstract

Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center

Tran

Taylor³

et al. 2022

Journal of Clinical Lipidology

View full text Add to dashboard Cite

Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures?

Cited by 2 publications

References 31 publications

Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis

Nanomaterial-Based Drug Targeted Therapy for Cardiovascular Diseases: Ischemic Heart Failure and Atherosclerosis

Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center

Contact Info

Product

Resources

About